Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial.

ABSTRACT:

Background

Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg^-1 min^-1 angiotensin II at 30 min (≤ 5 ng kg^-1 min^-1 subgroup) to maintain mean arterial pressure (MAP) ≥ 75 mmHg versus patients receiving > 5 ng kg^-1 min^-1 angiotensin II at 30 min (> 5 ng kg^-1 min^-1 subgroup). Data from angiotensin II-treated patients enrolled in the ATHOS-3 trial were used.

Results

The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg^-1 min^-1 at treatment initiation to ≤ 5 ng kg^-1 min

SUBMITTER: Ham KR 

PROVIDER: S-EPMC6546778 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature